MARKET

CTXR

CTXR

Citius Pharmaceuticals Inc
NASDAQ
1.100
+0.040
+3.77%
After Hours: 1.100 0 0.00% 16:10 12/16 EST
OPEN
1.050
PREV CLOSE
1.060
HIGH
1.110
LOW
1.040
VOLUME
180.36K
TURNOVER
--
52 WEEK HIGH
5.95
52 WEEK LOW
0.6500
MARKET CAP
20.32M
P/E (TTM)
-0.2215
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CTXR last week (1208-1212)?
Weekly Report · 1d ago
Citius Oncology Announces Warrant and Share Issuance in $18 Million Offering
Reuters · 6d ago
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Barchart · 6d ago
Citius Oncology announces $18 million registered direct offering
Seeking Alpha · 12/09 13:49
Citius Oncology Sells Shares and Warrants in $18 Million Private Placement
Reuters · 12/09 13:45
Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering
TipRanks · 12/09 13:35
CITIUS ONCOLOGY INC - PROCEEDS SUPPORT LAUNCH OF LYMPHIR FOR CUTANEOUS T-CELL LYMPHOMA
Reuters · 12/09 13:30
CITIUS ONCOLOGY INC - TO PURCHASE 1,284,404 SHARES OF COMMON STOCK AT $1.09 PER SHARE IN DIRECT OFFERING
Reuters · 12/09 13:30
More
About CTXR
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

Webull offers Citius Pharmaceuticals Inc stock information, including NASDAQ: CTXR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTXR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTXR stock methods without spending real money on the virtual paper trading platform.